{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:56:06Z","timestamp":1794027366208,"version":"4.8.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41569-021-00569-6","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T14:02:54Z","timestamp":1623679374000},"page":"809-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":930,"title":["PPAR control of metabolism and cardiovascular functions"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-863X","authenticated-orcid":false,"given":"David","family":"Montaigne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5760-1489","authenticated-orcid":false,"given":"Laura","family":"Butruille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-1503","authenticated-orcid":false,"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"key":"569_CR1","unstructured":"WHO. Cardiovascular diseases (CVDs). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (2017)."},{"key":"569_CR2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/ncpcardio1278","volume":"5","author":"B Staels","year":"2008","unstructured":"Staels, B., Maes, M. & Zambon, A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 5, 542\u2013553 (2008).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"569_CR3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross, B., Pawlak, M., Lefebvre, P. & Staels, B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat. Rev. Endocrinol. 13, 36\u201349 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"569_CR4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.tcb.2007.04.001","volume":"17","author":"JN Feige","year":"2007","unstructured":"Feige, J. N. & Auwerx, J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol. 17, 292\u2013301 (2007).","journal-title":"Trends Cell Biol."},{"key":"569_CR5","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 62, 720\u2013733 (2015).","journal-title":"J. Hepatol."},{"key":"569_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2004.11.005","volume":"1","author":"Y Oishi","year":"2005","unstructured":"Oishi, Y. et al. Kr\u00fcppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab. 1, 27\u201339 (2005).","journal-title":"Cell Metab."},{"key":"569_CR7","volume":"7","author":"H Lee","year":"2012","unstructured":"Lee, H. et al. Kr\u00fcppel-like factor KLF8 plays a critical role in adipocyte differentiation. PLoS ONE 7, e52474 (2012).","journal-title":"PLoS ONE"},{"key":"569_CR8","doi-asserted-by":"crossref","first-page":"14012","DOI":"10.1074\/jbc.RA118.004401","volume":"293","author":"Y Liu","year":"2018","unstructured":"Liu, Y. et al. Kr\u00fcppel-like factor 10 (KLF10) is transactivated by the transcription factor C\/EBP\u03b2 and involved in early 3T3-L1 preadipocyte differentiation. J. Biol. Chem. 293, 14012\u201314021 (2018).","journal-title":"J. Biol. Chem."},{"key":"569_CR9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCRESAHA.115.306383","volume":"118","author":"K Drosatos","year":"2016","unstructured":"Drosatos, K. et al. Cardiac myocyte KLF5 regulates Ppara expression and cardiac function. Circ. Res. 118, 241\u2013253 (2016).","journal-title":"Circ. Res."},{"key":"569_CR10","doi-asserted-by":"crossref","first-page":"201625","DOI":"10.1155\/2015\/201625","volume":"2015","author":"DA Prosdocimo","year":"2015","unstructured":"Prosdocimo, D. A. et al. KLF15 and PPAR\u03b1 cooperate to regulate cardiomyocyte lipid gene expression and oxidation. PPAR Res. 2015, 201625 (2015).","journal-title":"PPAR Res."},{"key":"569_CR11","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nm1756","volume":"14","author":"Y Oishi","year":"2008","unstructured":"Oishi, Y. et al. SUMOylation of Kr\u00fcppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat. Med. 14, 656\u2013666 (2008).","journal-title":"Nat. Med."},{"key":"569_CR12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","volume":"127","author":"V Dubois","year":"2017","unstructured":"Dubois, V., Eeckhoute, J., Lefebvre, P. & Staels, B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J. Clin. Invest. 127, 1202\u20131214 (2017).","journal-title":"J. Clin. Invest."},{"key":"569_CR13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne, N. et al. Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation. Endocr. Rev. 39, 760\u2013802 (2018).","journal-title":"Endocr. Rev."},{"key":"569_CR14","volume":"10","author":"Y Sasaki","year":"2020","unstructured":"Sasaki, Y. et al. Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci. Rep. 10, 7818 (2020).","journal-title":"Sci. Rep."},{"key":"569_CR15","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2011.10.029","volume":"220","author":"Y-J Choi","year":"2012","unstructured":"Choi, Y.-J. et al. Effects of the PPAR-\u03b4 agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220, 470\u2013476 (2012).","journal-title":"Atherosclerosis"},{"key":"569_CR16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00592-020-01487-8","volume":"57","author":"A Rastogi","year":"2020","unstructured":"Rastogi, A. et al. Abrogation of postprandial triglyceridemia with dual PPAR \u03b1\/\u03b3 agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study. Acta Diabetol. 57, 809\u2013818 (2020).","journal-title":"Acta Diabetol."},{"key":"569_CR17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","volume":"150","author":"V Ratziu","year":"2016","unstructured":"Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147\u20131159.e5 (2016).","journal-title":"Gastroenterology"},{"key":"569_CR18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","volume":"73","author":"S Lefere","year":"2020","unstructured":"Lefere, S. et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J. Hepatol. 73, 757\u2013770 (2020).","journal-title":"J. Hepatol."},{"key":"569_CR19","first-page":"546548","volume":"2012","author":"BK He","year":"2012","unstructured":"He, B. K. et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012, 546548 (2012).","journal-title":"PPAR Res."},{"key":"569_CR20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3390\/ijms17122093","volume":"17","author":"M Grabacka","year":"2016","unstructured":"Grabacka, M., Pierzchalska, M., Dean, M. & Reiss, K. Regulation of ketone body metabolism and the role of PPAR\u03b1. Int. J. Mol. Sci. 17, 2093 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"569_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2018.06.031","volume":"174","author":"D Guan","year":"2018","unstructured":"Guan, D. et al. Diet-induced circadian enhancer remodeling synchronizes opposing hepatic lipid metabolic processes. Cell 174, 831\u2013842.e12 (2018).","journal-title":"Cell"},{"key":"569_CR22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCHEARTFAILURE.112.000177","volume":"6","author":"K Drosatos","year":"2013","unstructured":"Drosatos, K. et al. Peroxisome proliferator-activated receptor-\u03b3 activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ. Heart Fail. 6, 550\u2013562 (2013).","journal-title":"Circ. Heart Fail."},{"key":"569_CR23","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jhep.2018.12.037","volume":"70","author":"R Paumelle","year":"2019","unstructured":"Paumelle, R. et al. Hepatic PPAR\u03b1 is critical in the metabolic adaptation to sepsis. J. Hepatol. 70, 963\u2013973 (2019).","journal-title":"J. Hepatol."},{"key":"569_CR24","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1172\/JCI97736","volume":"128","author":"S Seok","year":"2018","unstructured":"Seok, S. et al. Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid \u03b2-oxidation. J. Clin. Invest. 128, 3144\u20133159 (2018).","journal-title":"J. Clin. Invest."},{"key":"569_CR25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09598-9","volume":"10","author":"A Iershov","year":"2019","unstructured":"Iershov, A. et al. The class 3 PI3K coordinates autophagy and mitochondrial lipid catabolism by controlling nuclear receptor PPAR\u03b1. Nat. Commun. 10, 1566 (2019).","journal-title":"Nat. Commun."},{"key":"569_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.29786","volume":"68","author":"Z Zhao","year":"2018","unstructured":"Zhao, Z. et al. Hepatic PPAR\u03b1 function is controlled by polyubiquitination and proteasome-mediated degradation through the coordinated actions of PAQR3 and HUWE1. Hepatology 68, 289\u2013303 (2018).","journal-title":"Hepatology"},{"key":"569_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","volume":"65","author":"SM Francque","year":"2016","unstructured":"Francque, S. M., van der Graaff, D. & Kwanten, W. J. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J. Hepatol. 65, 425\u2013443 (2016).","journal-title":"J. Hepatol."},{"key":"569_CR28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","volume":"63","author":"S Francque","year":"2015","unstructured":"Francque, S. et al. PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J. Hepatol. 63, 164\u2013173 (2015).","journal-title":"J. Hepatol."},{"key":"569_CR29","volume":"10","author":"N Liang","year":"2019","unstructured":"Liang, N. et al. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR\u03b1. Nat. Commun. 10, 1684 (2019).","journal-title":"Nat. Commun."},{"key":"569_CR30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","volume":"65","author":"A Montagner","year":"2016","unstructured":"Montagner, A. et al. Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202\u20131214 (2016).","journal-title":"Gut"},{"key":"569_CR31","doi-asserted-by":"crossref","first-page":"R733","DOI":"10.1152\/ajpregu.00153.2019","volume":"317","author":"DE Stec","year":"2019","unstructured":"Stec, D. E. et al. Loss of hepatic PPAR\u03b1 promotes inflammation and serum hyperlipidemia in diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 317, R733\u2013R745 (2019).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"569_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63579-3","volume":"10","author":"M R\u00e9gnier","year":"2020","unstructured":"R\u00e9gnier, M. et al. Hepatocyte-specific deletion of Ppar\u03b1 promotes NAFLD in the context of obesity. Sci. Rep. 10, 6489 (2020).","journal-title":"Sci. Rep."},{"key":"569_CR33","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1194\/jlr.M088419","volume":"59","author":"CN Brocker","year":"2018","unstructured":"Brocker, C. N. et al. Extrahepatic PPAR\u03b1 modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. J. Lipid Res. 59, 2140\u20132152 (2018).","journal-title":"J. Lipid Res."},{"key":"569_CR34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","volume":"18","author":"G Gaich","year":"2013","unstructured":"Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333\u2013340 (2013).","journal-title":"Cell Metab."},{"key":"569_CR35","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392, 2705\u20132717 (2019).","journal-title":"Lancet"},{"key":"569_CR36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","volume":"41","author":"M Zarei","year":"2020","unstructured":"Zarei, M., Pizarro-Delgado, J., Barroso, E., Palomer, X. & V\u00e1zquez-Carrera, M. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol. Sci. 41, 199\u2013208 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"569_CR37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","volume":"249","author":"N Hennuyer","year":"2016","unstructured":"Hennuyer, N. et al. The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis 249, 200\u2013208 (2016).","journal-title":"Atherosclerosis"},{"key":"569_CR38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5551\/jat.39693","volume":"25","author":"M Sairyo","year":"2018","unstructured":"Sairyo, M. et al. A novel selective PPAR\u03b1 modulator (SPPARM\u03b1), K-877 (pemafibrate), attenuates postprandial hypertriglyceridemia in mice. J. Atheroscler. Thromb. 25, 142\u2013152 (2018).","journal-title":"J. Atheroscler. Thromb."},{"key":"569_CR39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2015.03.011","volume":"9","author":"A Othman","year":"2015","unstructured":"Othman, A. et al. Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? J. Clin. Lipidol. 9, 568\u2013575 (2015).","journal-title":"J. Clin. Lipidol."},{"key":"569_CR40","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s00125-019-04973-z","volume":"62","author":"LJ Holm","year":"2019","unstructured":"Holm, L. J. et al. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice. Diabetologia 62, 2262\u20132272 (2019).","journal-title":"Diabetologia"},{"key":"569_CR41","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849\u20131861 (2005).","journal-title":"Lancet"},{"key":"569_CR42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"ACCORD Study Group","year":"2010","unstructured":"ACCORD Study Group et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563\u20131574 (2010).","journal-title":"N. Engl. J. Med."},{"key":"569_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07014-9","author":"J Guti\u00e9rrez-Cuevas","year":"2020","unstructured":"Guti\u00e9rrez-Cuevas, J. et al. Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-020-07014-9 (2020).","journal-title":"Cardiovasc Drugs Ther."},{"key":"569_CR44","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/en.2010-1468","volume":"152","author":"E Barroso","year":"2011","unstructured":"Barroso, E. et al. The PPAR\u03b2\/\u03b4 activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1\u03b1-lipin 1-PPAR\u03b1 pathway leading to increased fatty acid oxidation. Endocrinology 152, 1848\u20131859 (2011).","journal-title":"Endocrinology"},{"key":"569_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","volume":"8","author":"M Zarei","year":"2018","unstructured":"Zarei, M. et al. Hepatic regulation of VLDL receptor by PPAR\u03b2\/\u03b4 and FGF21 modulates non-alcoholic fatty liver disease. Mol. Metab. 8, 117\u2013131 (2018).","journal-title":"Mol. Metab."},{"key":"569_CR46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","volume":"232","author":"A Wolf Greenstein","year":"2017","unstructured":"Wolf Greenstein, A. et al. Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice. J. Endocrinol. 232, 107\u2013121 (2017).","journal-title":"J. Endocrinol."},{"key":"569_CR47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3892\/mmr.2014.2846","volume":"11","author":"X Li","year":"2015","unstructured":"Li, X. et al. MicroRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor \u03b3. Mol. Med. Rep. 11, 1017\u20131024 (2015).","journal-title":"Mol. Med. Rep."},{"key":"569_CR48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41569-018-0097-6","volume":"16","author":"EK Oikonomou","year":"2019","unstructured":"Oikonomou, E. K. & Antoniades, C. The role of adipose tissue in cardiovascular health and disease. Nat. Rev. Cardiol. 16, 83\u201399 (2019).","journal-title":"Nat. Rev. Cardiol."},{"key":"569_CR49","first-page":"e137","volume":"38","author":"EE Ha","year":"2018","unstructured":"Ha, E. E. & Bauer, R. C. Emerging roles for adipose tissue in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 38, e137\u2013e144 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"569_CR50","doi-asserted-by":"crossref","first-page":"108228","DOI":"10.1016\/j.celrep.2020.108228","volume":"33","author":"JM Dean","year":"2020","unstructured":"Dean, J. M. et al. MED19 regulates adipogenesis and maintenance of white adipose tissue mass by mediating PPAR\u03b3-dependent gene expression. Cell Rep. 33, 108228 (2020).","journal-title":"Cell Rep."},{"key":"569_CR51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cmet.2019.10.003","volume":"31","author":"D El Ouarrat","year":"2020","unstructured":"El Ouarrat, D. et al. TAZ is a negative regulator of PPAR\u03b3 activity in adipocytes and TAZ deletion improves insulin sensitivity and glucose tolerance. Cell Metab. 31, 162\u2013173.e5 (2020).","journal-title":"Cell Metab."},{"key":"569_CR52","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3262","volume":"4","author":"K Fujiki","year":"2013","unstructured":"Fujiki, K. et al. PPAR\u03b3-induced PARylation promotes local DNA demethylation by production of 5-hydroxymethylcytosine. Nat. Commun. 4, 2262 (2013).","journal-title":"Nat. Commun."},{"key":"569_CR53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.metabol.2018.08.006","volume":"89","author":"F Bian","year":"2018","unstructured":"Bian, F. et al. TET2 facilitates PPAR\u03b3 agonist-mediated gene regulation and insulin sensitization in adipocytes. Metab. Clin. Exp. 89, 39\u201347 (2018).","journal-title":"Metab. Clin. Exp."},{"key":"569_CR54","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.celrep.2018.05.065","volume":"23","author":"J Peng","year":"2018","unstructured":"Peng, J. et al. An Hsp20-FBXO4 axis regulates adipocyte function through modulating PPAR\u03b3 ubiquitination. Cell Rep. 23, 3607\u20133620 (2018).","journal-title":"Cell Rep."},{"key":"569_CR55","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.celrep.2018.07.063","volume":"24","author":"S Virtue","year":"2018","unstructured":"Virtue, S. et al. Peroxisome proliferator-activated receptor \u03b32 controls the rate of adipose tissue lipid storage and determines metabolic flexibility. Cell Rep. 24, 2005\u20132012.e7 (2018).","journal-title":"Cell Rep."},{"key":"569_CR56","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1073\/pnas.1814522115","volume":"115","author":"T Katafuchi","year":"2018","unstructured":"Katafuchi, T. et al. PPAR\u03b3-K107 SUMOylation regulates insulin sensitivity but not adiposity in mice. Proc. Natl Acad. Sci. USA 115, 12102\u201312111 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"569_CR57","doi-asserted-by":"crossref","first-page":"38768","DOI":"10.1074\/jbc.M006450200","volume":"275","author":"C Bastie","year":"2000","unstructured":"Bastie, C., Luquet, S., Holst, D., Jehl-Pietri, C. & Grimaldi, P. A. Alterations of peroxisome proliferator-activated receptor delta activity affect fatty acid-controlled adipose differentiation. J. Biol. Chem. 275, 38768\u201338773 (2000).","journal-title":"J. Biol. Chem."},{"key":"569_CR58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cmet.2008.04.002","volume":"7","author":"K Kang","year":"2008","unstructured":"Kang, K. et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485\u2013495 (2008).","journal-title":"Cell Metab."},{"key":"569_CR59","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","volume":"113","author":"Y-X Wang","year":"2003","unstructured":"Wang, Y.-X. et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113, 159\u2013170 (2003).","journal-title":"Cell"},{"key":"569_CR60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00889-z","volume":"7","author":"M Doktorova","year":"2017","unstructured":"Doktorova, M. et al. Intestinal PPAR\u03b4 protects against diet-induced obesity, insulin resistance and dyslipidemia. Sci. Rep. 7, 846 (2017).","journal-title":"Sci. Rep."},{"key":"569_CR61","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","volume":"96","author":"HE Bays","year":"2011","unstructured":"Bays, H. E. et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96, 2889\u20132897 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"569_CR62","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cell.2012.06.027","volume":"150","author":"L Qiang","year":"2012","unstructured":"Qiang, L. et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppar\u03b3. Cell 150, 620\u2013632 (2012).","journal-title":"Cell"},{"key":"569_CR63","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","volume":"32","author":"JA Hall","year":"2020","unstructured":"Hall, J. A. et al. Obesity-linked PPAR\u03b3 S273 phosphorylation promotes insulin resistance through growth differentiation factor 3. Cell Metab. 32, 665\u2013675.e6 (2020).","journal-title":"Cell Metab."},{"key":"569_CR64","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1172\/JCI98709","volume":"128","author":"MJ Kraakman","year":"2018","unstructured":"Kraakman, M. J. et al. PPAR\u03b3 deacetylation dissociates thiazolidinedione\u2019s metabolic benefits from its adverse effects. J. Clin. Invest. 128, 2600\u20132612 (2018).","journal-title":"J. Clin. Invest."},{"key":"569_CR65","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1074\/jbc.M006246200","volume":"276","author":"MJ Barbera","year":"2001","unstructured":"Barbera, M. J. et al. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J. Biol. Chem. 276, 1486\u20131493 (2001).","journal-title":"J. Biol. Chem."},{"key":"569_CR66","doi-asserted-by":"crossref","first-page":"43112","DOI":"10.1074\/jbc.M111.252775","volume":"286","author":"E Hondares","year":"2011","unstructured":"Hondares, E. et al. Peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) induces PPAR\u03b3 coactivator 1\u03b1 (PGC-1\u03b1) gene expression and contributes to thermogenic activation of brown fat: involvement of PRDM16. J. Biol. Chem. 286, 43112\u201343122 (2011).","journal-title":"J. Biol. Chem."},{"key":"569_CR67","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mce.2014.12.027","volume":"402","author":"TL Rachid","year":"2015","unstructured":"Rachid, T. L. et al. Fenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese mice. Mol. Cell. Endocrinol. 402, 86\u201394 (2015).","journal-title":"Mol. Cell. Endocrinol."},{"key":"569_CR68","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2337\/db17-1452","volume":"67","author":"L Zhou","year":"2018","unstructured":"Zhou, L. et al. Coordination among lipid droplets, peroxisomes, and mitochondria regulates energy expenditure through the CIDE-ATGL-PPAR\u03b1 pathway in adipocytes. Diabetes 67, 1935\u20131948 (2018).","journal-title":"Diabetes"},{"key":"569_CR69","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.metabol.2004.05.003","volume":"53","author":"S Jeong","year":"2004","unstructured":"Jeong, S. et al. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL\/6J mice. Metabolism 53, 1284\u20131289 (2004).","journal-title":"Metabolism"},{"key":"569_CR70","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/ATVBAHA.118.311367","volume":"38","author":"W Xiong","year":"2018","unstructured":"Xiong, W. et al. Brown adipocyte-specific PPAR\u03b3 (peroxisome proliferator-activated receptor \u03b3) deletion impairs perivascular adipose tissue development and enhances atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 38, 1738\u20131747 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"569_CR71","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M. & Drucker, D. J. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136, 849\u2013870 (2017).","journal-title":"Circulation"},{"key":"569_CR72","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/eurheartj\/ehaa174","volume":"41","author":"N Marx","year":"2020","unstructured":"Marx, N. Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur. Heart J. 41, 3359\u20133362 (2020).","journal-title":"Eur. Heart J."},{"key":"569_CR73","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCRESAHA.117.309715","volume":"120","author":"WHW Tang","year":"2017","unstructured":"Tang, W. H. W., Kitai, T. & Hazen, S. L. Gut microbiota in cardiovascular health and disease. Circ. Res. 120, 1183\u20131196 (2017).","journal-title":"Circ. Res."},{"key":"569_CR74","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.2337\/db14-1213","volume":"64","author":"G den Besten","year":"2015","unstructured":"den Besten, G. et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPAR\u03b3-dependent switch from lipogenesis to fat oxidation. Diabetes 64, 2398\u20132408 (2015).","journal-title":"Diabetes"},{"key":"569_CR75","doi-asserted-by":"crossref","DOI":"10.1038\/srep43199","volume":"7","author":"M Nepelska","year":"2017","unstructured":"Nepelska, M. et al. Commensal gut bacteria modulate phosphorylation-dependent PPAR\u03b3 transcriptional activity in human intestinal epithelial cells. Sci. Rep. 7, 43199 (2017).","journal-title":"Sci. Rep."},{"key":"569_CR76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.aam9949","volume":"357","author":"MX Byndloss","year":"2017","unstructured":"Byndloss, M. X. et al. Microbiota-activated PPAR-\u03b3 signaling inhibits dysbiotic Enterobacteriaceae expansion. Science 357, 570\u2013575 (2017).","journal-title":"Science"},{"key":"569_CR77","doi-asserted-by":"crossref","first-page":"E5934","DOI":"10.1073\/pnas.1612559113","volume":"113","author":"J Tomas","year":"2016","unstructured":"Tomas, J. et al. High-fat diet modifies the PPAR-\u03b3 pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proc. Natl Acad. Sci. USA 113, E5934\u2013E5943 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"569_CR78","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29815-7","volume":"8","author":"K Duszka","year":"2018","unstructured":"Duszka, K. et al. Complementary intestinal mucosa and microbiota responses to caloric restriction. Sci. Rep. 8, 11338 (2018).","journal-title":"Sci. Rep."},{"key":"569_CR79","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1093\/eurheartj\/ehs227","volume":"34","author":"S Colin","year":"2013","unstructured":"Colin, S. et al. Activation of intestinal peroxisome proliferator-activated receptor-\u03b1 increases high-density lipoprotein production. Eur. Heart J. 34, 2566\u20132574 (2013).","journal-title":"Eur. Heart J."},{"key":"569_CR80","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jphs.2017.02.003","volume":"133","author":"K Takei","year":"2017","unstructured":"Takei, K. et al. Effects of K-877, a novel selective PPAR\u03b1 modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice. J. Pharmacol. Sci. 133, 214\u2013222 (2017).","journal-title":"J. Pharmacol. Sci."},{"key":"569_CR81","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2011.01.045","volume":"140","author":"M Daoudi","year":"2011","unstructured":"Daoudi, M. et al. PPAR\u03b2\/\u03b4 activation induces enteroendocrine L cell GLP-1 production. Gastroenterology 140, 1564\u20131574 (2011).","journal-title":"Gastroenterology"},{"key":"569_CR82","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1096\/fj.03-0269fje","volume":"17","author":"S Luquet","year":"2003","unstructured":"Luquet, S. et al. Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J. 17, 2299\u20132301 (2003).","journal-title":"FASEB J."},{"key":"569_CR83","volume":"2","author":"Y-X Wang","year":"2004","unstructured":"Wang, Y.-X. et al. Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol. 2, e294 (2004).","journal-title":"PLoS Biol."},{"key":"569_CR84","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.cmet.2017.04.029","volume":"25","author":"J-H Koh","year":"2017","unstructured":"Koh, J.-H. et al. PPAR\u03b2 is essential for maintaining normal levels of PGC-1\u03b1 and mitochondria and for the increase in muscle mitochondria induced by exercise. Cell Metab. 25, 1176\u20131185.e5 (2017).","journal-title":"Cell Metab."},{"key":"569_CR85","doi-asserted-by":"crossref","first-page":"E931","DOI":"10.1152\/ajpendo.00460.2018","volume":"316","author":"J-H Koh","year":"2019","unstructured":"Koh, J.-H. et al. AMPK and PPAR\u03b2 positive feedback loop regulates endurance exercise training-mediated GLUT4 expression in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 316, E931\u2013E939 (2019).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"569_CR86","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.3390\/ijms20205182","volume":"20","author":"S Le Garf","year":"2019","unstructured":"Le Garf, S. et al. Complementary immunometabolic effects of exercise and PPAR\u03b2\/\u03b4 agonist in the context of diet-induced weight loss in obese female mice. Int. J. Mol. Sci. 20, 5182 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"569_CR87","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.cmet.2017.04.006","volume":"25","author":"W Fan","year":"2017","unstructured":"Fan, W. et al. PPAR\u03b4 promotes running endurance by preserving glucose. Cell Metab. 25, 1186\u20131193.e4 (2017).","journal-title":"Cell Metab."},{"key":"569_CR88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmet.2005.01.006","volume":"1","author":"BN Finck","year":"2005","unstructured":"Finck, B. N. et al. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab. 1, 133\u2013144 (2005).","journal-title":"Cell Metab."},{"key":"569_CR89","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1159\/000430399","volume":"37","author":"S Bhattacharjee","year":"2015","unstructured":"Bhattacharjee, S., Das, N., Mandala, A., Mukhopadhyay, S. & Roy, S. S. Fenofibrate reverses palmitate induced impairment in glucose uptake in skeletal muscle cells by preventing cytosolic ceramide accumulation. Cell. Physiol. Biochem. 37, 1315\u20131328 (2015).","journal-title":"Cell. Physiol. Biochem."},{"key":"569_CR90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby, P. et al. Atherosclerosis. Nat. Rev. Dis. Prim. 5, 56 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"569_CR91","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvx226","volume":"114","author":"S Mundi","year":"2018","unstructured":"Mundi, S. et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review. Cardiovasc. Res. 114, 35\u201352 (2018).","journal-title":"Cardiovasc. Res."},{"key":"569_CR92","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/01.RES.0000127122.22685.0A","volume":"94","author":"N Marx","year":"2004","unstructured":"Marx, N., Duez, H., Fruchart, J.-C. & Staels, B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94, 1168\u20131178 (2004).","journal-title":"Circ. Res."},{"key":"569_CR93","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/HYPERTENSIONAHA.117.10799","volume":"72","author":"TM De Silva","year":"2018","unstructured":"De Silva, T. M., Li, Y., Kinzenbaw, D. A., Sigmund, C. D. & Faraci, F. M. Endothelial PPAR\u03b3 (peroxisome proliferator-activated receptor-\u03b3) is essential for preventing endothelial dysfunction with aging. Hypertension 72, 227\u2013234 (2018).","journal-title":"Hypertension"},{"key":"569_CR94","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.celrep.2019.01.013","volume":"26","author":"CG Li","year":"2019","unstructured":"Li, C. G. et al. PPAR\u03b3 interaction with UBR5\/ATMIN promotes DNA repair to maintain endothelial homeostasis. Cell Rep. 26, 1333\u20131343.e7 (2019).","journal-title":"Cell Rep."},{"key":"569_CR95","volume":"8","author":"H Mao","year":"2017","unstructured":"Mao, H. et al. Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPAR\u03b3. Nat. Commun. 8, 14960 (2017).","journal-title":"Nat. Commun."},{"key":"569_CR96","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cmet.2017.03.011","volume":"25","author":"L Calvier","year":"2017","unstructured":"Calvier, L. et al. PPAR\u03b3 links BMP2 and TGF\u03b21 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab. 25, 1118\u20131134.e7 (2017).","journal-title":"Cell Metab."},{"key":"569_CR97","volume":"6","author":"J Yu","year":"2016","unstructured":"Yu, J. et al. DNMT1-PPAR\u03b3 pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice. Sci. Rep. 6, 30053 (2016).","journal-title":"Sci. Rep."},{"key":"569_CR98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","volume":"6","author":"MA Bouhlel","year":"2007","unstructured":"Bouhlel, M. A. et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137\u2013143 (2007).","journal-title":"Cell Metab."},{"key":"569_CR99","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1101\/gad.312355.118","volume":"32","author":"VL Nelson","year":"2018","unstructured":"Nelson, V. L. et al. PPAR\u03b3 is a nexus controlling alternative activation of macrophages via glutamine metabolism. Genes Dev. 32, 1035\u20131044 (2018).","journal-title":"Genes Dev."},{"key":"569_CR100","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.cell.2019.07.050","volume":"178","author":"S Jordan","year":"2019","unstructured":"Jordan, S. et al. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 178, 1102\u20131114.e17 (2019).","journal-title":"Cell"},{"key":"569_CR101","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1073\/pnas.0711875105","volume":"105","author":"GD Barish","year":"2008","unstructured":"Barish, G. D. et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl Acad. Sci. USA 105, 4271\u20134276 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"569_CR102","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.2337\/db12-0117","volume":"61","author":"XY Tian","year":"2012","unstructured":"Tian, X. Y. et al. PPAR\u03b4 activation protects endothelial function in diabetic mice. Diabetes 61, 3285\u20133293 (2012).","journal-title":"Diabetes"},{"key":"569_CR103","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bcp.2016.05.004","volume":"110\u2013111","author":"M Toral","year":"2016","unstructured":"Toral, M. et al. Role of UCP2 in the protective effects of PPAR\u03b2\/\u03b4 activation on lipopolysaccharide-induced endothelial dysfunction. Biochem. Pharmacol. 110\u2013111, 25\u201336 (2016).","journal-title":"Biochem. Pharmacol."},{"key":"569_CR104","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1111\/bph.13160","volume":"172","author":"X Fang","year":"2015","unstructured":"Fang, X. et al. Activation of PPAR-\u03b4 induces microRNA-100 and decreases the uptake of very low-density lipoprotein in endothelial cells. Br. J. Pharmacol. 172, 3728\u20133736 (2015).","journal-title":"Br. J. Pharmacol."},{"key":"569_CR105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1124\/mol.116.104679","volume":"90","author":"JS Hwang","year":"2016","unstructured":"Hwang, J. S. et al. Sirtuin 1 mediates the actions of peroxisome proliferator-activated receptor \u03b4 on the oxidized low-density lipoprotein-triggered migration and proliferation of vascular smooth muscle cells. Mol. Pharmacol. 90, 522\u2013529 (2016).","journal-title":"Mol. Pharmacol."},{"key":"569_CR106","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/hc4601.099403","volume":"104","author":"TL Yue","year":"2001","unstructured":"Yue, T. L. et al. In vivo myocardial protection from ischemia\/reperfusion injury by the peroxisome proliferator\u2013activated receptor-\u03b3 agonist rosiglitazone. Circulation 104, 2588\u20132594 (2001).","journal-title":"Circulation"},{"key":"569_CR107","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1161\/01.CIR.0000093187.42015.6C","volume":"108","author":"T Yue","year":"2003","unstructured":"Yue, T. et al. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia\/reperfusion injury. Circulation 108, 2393\u20132399 (2003).","journal-title":"Circulation"},{"key":"569_CR108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/SHK.0b013e3181cd86d6","volume":"34","author":"A Kapoor","year":"2010","unstructured":"Kapoor, A., Collino, M., Castiglia, S., Fantozzi, R. & Thiemermann, C. Activation of peroxisome proliferator-activated receptor-beta\/delta attenuates myocardial ischemia\/reperfusion injury in the rat. Shock 34, 117\u2013124 (2010).","journal-title":"Shock"},{"key":"569_CR109","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.1074\/jbc.M111.220525","volume":"286","author":"H el Azzouzi","year":"2011","unstructured":"el Azzouzi, H. et al. Peroxisome proliferator-activated receptor (PPAR) gene profiling uncovers insulin-like growth factor-1 as a PPARalpha target gene in cardioprotection. J. Biol. Chem. 286, 14598\u201314607 (2011).","journal-title":"J. Biol. Chem."},{"key":"569_CR110","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diabetes.54.2.554","volume":"54","author":"T-L Yue","year":"2005","unstructured":"Yue, T.-L. et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia\/reperfusion-induced myocardial injury. Diabetes 54, 554\u2013562 (2005).","journal-title":"Diabetes"},{"key":"569_CR111","doi-asserted-by":"crossref","first-page":"H895","DOI":"10.1152\/ajpheart.00137.2011","volume":"301","author":"A Morrison","year":"2011","unstructured":"Morrison, A., Yan, X., Tong, C. & Li, J. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am. J. Physiol. Heart Circ. Physiol. 301, H895\u2013H902 (2011).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"569_CR112","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","volume":"55","author":"AH Xiang","year":"2006","unstructured":"Xiang, A. H. et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55, 517\u2013522 (2006).","journal-title":"Diabetes"},{"key":"569_CR113","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279\u20131289 (2005).","journal-title":"Lancet"},{"key":"569_CR114","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"Kernan, W. N. et al. Pioglitazone after ischemic stroke or transient ischemic attack. N. Engl. J. Med. 374, 1321\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"569_CR115","volume":"5","author":"C Kalliora","year":"2019","unstructured":"Kalliora, C. et al. Dual peroxisome-proliferator-activated-receptor-\u03b1\/\u03b3 activation inhibits SIRT1-PGC1\u03b1 axis and causes cardiac dysfunction. JCI Insight 5, e129556 (2019).","journal-title":"JCI Insight"},{"key":"569_CR116","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","volume":"97","author":"SZ Duan","year":"2005","unstructured":"Duan, S. Z., Ivashchenko, C. Y., Russell, M. W., Milstone, D. S. & Mortensen, R. M. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ. Res. 97, 372\u2013379 (2005).","journal-title":"Circ. Res."},{"key":"569_CR117","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1210\/en.2006-1559","volume":"148","author":"S Sena","year":"2007","unstructured":"Sena, S. et al. Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148, 6047\u20136053 (2007).","journal-title":"Endocrinology"},{"key":"569_CR118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035999","volume":"7","author":"M Barbieri","year":"2012","unstructured":"Barbieri, M. et al. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-\u03b3-knockout (CM-PGKO) mice. PLoS ONE 7, e35999 (2012).","journal-title":"PLoS ONE"},{"key":"569_CR119","unstructured":"US National Library of Medicine. Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT). ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071692 (2017)."},{"key":"569_CR120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","volume":"206","author":"AD Pradhan","year":"2018","unstructured":"Pradhan, A. D. et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am. Heart J. 206, 80\u201393 (2018).","journal-title":"Am. Heart J."},{"key":"569_CR121","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki, E. et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41, 538\u2013546 (2018).","journal-title":"Diabetes Care"},{"key":"569_CR122","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi, S. et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol. 12, 173\u2013184 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"569_CR123","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.yjmcc.2008.03.021","volume":"44","author":"JA Madrazo","year":"2008","unstructured":"Madrazo, J. A. & Kelly, D. P. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J. Mol. Cell. Cardiol. 44, 968\u2013975 (2008).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"569_CR124","first-page":"835985","volume":"2015","author":"CJ Pol","year":"2015","unstructured":"Pol, C. J., Lieu, M. & Drosatos, K. PPARs: protectors or opponents of myocardial function? PPAR Res. 2015, 835985 (2015).","journal-title":"PPAR Res."},{"key":"569_CR125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1440-1681.2002.03655.x","volume":"29","author":"JJ Lehman","year":"2002","unstructured":"Lehman, J. J. & Kelly, D. P. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin. Exp. Pharmacol. Physiol. 29, 339\u2013345 (2002).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"569_CR126","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.bbamcr.2016.02.011","volume":"1863","author":"P Mirtschink","year":"2016","unstructured":"Mirtschink, P. & Krek, W. Hypoxia-driven glycolytic and fructolytic metabolic programs: Pivotal to hypertrophic heart disease. Biochim. Biophys. Acta 1863, 1822\u20131828 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"569_CR127","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","volume":"126","author":"J Ritterhoff","year":"2020","unstructured":"Ritterhoff, J. et al. Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis. Circ. Res. 126, 182\u2013196 (2020).","journal-title":"Circ. Res."},{"key":"569_CR128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","volume":"33","author":"AA Cluntun","year":"2021","unstructured":"Cluntun, A. A. et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab. 33, 629\u2013648.E10 (2021).","journal-title":"Cell Metab."},{"key":"569_CR129","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s42255-020-00288-1","volume":"2","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Mitochondrial pyruvate carriers are required for myocardial stress adaptation. Nat. Metab. 2, 1248\u20131264 (2020).","journal-title":"Nat. Metab."},{"key":"569_CR130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s42255-020-0169-x","volume":"2","author":"AC Cardoso","year":"2020","unstructured":"Cardoso, A. C. et al. Mitochondrial substrate utilization regulates cardiomyocyte cell cycle progression. Nat. Metab. 2, 167\u2013178 (2020).","journal-title":"Nat. Metab."},{"key":"569_CR131","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/cvr\/26.12.1172","volume":"26","author":"GD Lopaschuk","year":"1992","unstructured":"Lopaschuk, G. D., Collins-Nakai, R. L. & Itoi, T. Developmental changes in energy substrate use by the heart. Cardiovasc. Res. 26, 1172\u20131180 (1992).","journal-title":"Cardiovasc. Res."},{"key":"569_CR132","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1101\/gad.269894.115","volume":"29","author":"GW Dorn","year":"2015","unstructured":"Dorn, G. W., Vega, R. B. & Kelly, D. P. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes Dev. 29, 1981\u20131991 (2015).","journal-title":"Genes Dev."},{"key":"569_CR133","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI30335","volume":"117","author":"N-H Son","year":"2007","unstructured":"Son, N.-H. et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791\u20132801 (2007).","journal-title":"J. Clin. Invest."},{"key":"569_CR134","doi-asserted-by":"crossref","first-page":"22293","DOI":"10.1074\/jbc.M000248200","volume":"275","author":"K Watanabe","year":"2000","unstructured":"Watanabe, K. et al. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J. Biol. Chem. 275, 22293\u201322299 (2000).","journal-title":"J. Biol. Chem."},{"key":"569_CR135","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1074\/jbc.M106054200","volume":"277","author":"FM Campbell","year":"2002","unstructured":"Campbell, F. M. et al. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J. Biol. Chem. 277, 4098\u20134103 (2002).","journal-title":"J. Biol. Chem."},{"key":"569_CR136","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.96.13.7473","volume":"96","author":"TC Leone","year":"1999","unstructured":"Leone, T. C., Weinheimer, C. J. & Kelly, D. P. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc. Natl Acad. Sci. USA 96, 7473\u20137478 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"569_CR137","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1161\/CIRCULATIONAHA.105.534594","volume":"112","author":"I Luptak","year":"2005","unstructured":"Luptak, I. et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112, 2339\u20132346 (2005).","journal-title":"Circulation"},{"key":"569_CR138","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/nm.2439","volume":"17","author":"G Haemmerle","year":"2011","unstructured":"Haemmerle, G. et al. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-\u03b1 and PGC-1. Nat. Med. 17, 1076\u20131085 (2011).","journal-title":"Nat. Med."},{"key":"569_CR139","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","volume":"109","author":"BN Finck","year":"2002","unstructured":"Finck, B. N. et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121\u2013130 (2002).","journal-title":"J. Clin. Invest."},{"key":"569_CR140","first-page":"3930","volume":"117","author":"EM Burkart","year":"2007","unstructured":"Burkart, E. M. et al. Nuclear receptors PPARbeta\/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117, 3930\u20133939 (2007).","journal-title":"J. Clin. Invest."},{"key":"569_CR141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/HYPERTENSIONAHA.110.164590","volume":"57","author":"J Liu","year":"2011","unstructured":"Liu, J. et al. Peroxisome proliferator-activated receptor \u03b2\/\u03b4 activation in adult hearts facilitates mitochondrial function and cardiac performance under pressure-overload condition. Hypertension 57, 223\u2013230 (2011).","journal-title":"Hypertension"},{"key":"569_CR142","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm1116","volume":"10","author":"L Cheng","year":"2004","unstructured":"Cheng, L. et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245\u20131250 (2004).","journal-title":"Nat. Med."},{"key":"569_CR143","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cardiores.2007.06.027","volume":"76","author":"G Ding","year":"2007","unstructured":"Ding, G. et al. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc. Res. 76, 269\u2013279 (2007).","journal-title":"Cardiovasc. Res."},{"key":"569_CR144","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1172\/JCI40905","volume":"120","author":"N-H Son","year":"2010","unstructured":"Son, N.-H. et al. PPAR\u03b3-induced cardiolipotoxicity in mice is ameliorated by PPAR\u03b1 deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120, 3443\u20133454 (2010).","journal-title":"J. Clin. Invest."},{"key":"569_CR145","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.bbalip.2014.09.012","volume":"1841","author":"M Bosma","year":"2014","unstructured":"Bosma, M. et al. Sequestration of fatty acids in triglycerides prevents endoplasmic reticulum stress in an in vitro model of cardiomyocyte lipotoxicity. Biochim. Biophys. Acta 1841, 1648\u20131655 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"569_CR146","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero, E. & Maack, C. Metabolic remodelling in heart failure. Nat. Rev. Cardiol. 15, 457\u2013470 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"569_CR147","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacbts.2016.11.009","volume":"2","author":"AR Wende","year":"2017","unstructured":"Wende, A. R., Brahma, M. K., McGinnis, G. R. & Young, M. E. Metabolic origins of heart failure. JACC Basic. Transl. Sci. 2, 297\u2013310 (2017).","journal-title":"JACC Basic. Transl. Sci."},{"key":"569_CR148","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.cmet.2009.05.005","volume":"9","author":"J Krishnan","year":"2009","unstructured":"Krishnan, J. et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab. 9, 512\u2013524 (2009).","journal-title":"Cell Metab."},{"key":"569_CR149","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.110.977066","volume":"123","author":"P Shende","year":"2011","unstructured":"Shende, P. et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation 123, 1073\u20131082 (2011).","journal-title":"Circulation"},{"key":"569_CR150","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI9056","volume":"105","author":"PM Barger","year":"2000","unstructured":"Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J. & Kelly, D. P. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723\u20131730 (2000).","journal-title":"J. Clin. Invest."},{"key":"569_CR151","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1096\/fj.201500094R","volume":"30","author":"MA Cole","year":"2016","unstructured":"Cole, M. A. et al. On the pivotal role of PPAR\u03b1 in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury. FASEB J. 30, 2684\u20132697 (2016).","journal-title":"FASEB J."},{"key":"569_CR152","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2013.08.009","volume":"18","author":"H el Azzouzi","year":"2013","unstructured":"el Azzouzi, H. et al. The hypoxia-inducible microRNA cluster miR-199a\u223c214 targets myocardial PPAR\u03b4 and impairs mitochondrial fatty acid oxidation. Cell Metab. 18, 341\u2013354 (2013).","journal-title":"Cell Metab."},{"key":"569_CR153","volume":"11","author":"DH Tran","year":"2020","unstructured":"Tran, D. H. et al. Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling. Nat. Commun. 11, 1771 (2020).","journal-title":"Nat. Commun."},{"key":"569_CR154","doi-asserted-by":"crossref","first-page":"H3270","DOI":"10.1152\/ajpheart.00887.2007","volume":"293","author":"D Neglia","year":"2007","unstructured":"Neglia, D. et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 293, H3270\u2013H3278 (2007).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"569_CR155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","volume":"370","author":"D Murashige","year":"2020","unstructured":"Murashige, D. et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science 370, 364\u2013368 (2020).","journal-title":"Science"},{"key":"569_CR156","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/CIRCRESAHA.116.306842","volume":"118","author":"PC Schulze","year":"2016","unstructured":"Schulze, P. C., Drosatos, K. & Goldberg, I. J. Lipid use and misuse by the heart. Circ. Res. 118, 1736\u20131751 (2016).","journal-title":"Circ. Res."},{"key":"569_CR157","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/eurheartj\/ehv120","volume":"36","author":"S Dass","year":"2015","unstructured":"Dass, S. et al. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur. Heart J. 36, 1547\u20131554 (2015).","journal-title":"Eur. Heart J."},{"key":"569_CR158","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/db15-0627","volume":"65","author":"E Levelt","year":"2016","unstructured":"Levelt, E. et al. Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes. Diabetes 65, 44\u201352 (2016).","journal-title":"Diabetes"},{"key":"569_CR159","doi-asserted-by":"crossref","first-page":"E452","DOI":"10.1152\/ajpendo.00437.2015","volume":"310","author":"KJ Mather","year":"2016","unstructured":"Mather, K. J. et al. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. Am. J. Physiol. Endocrinol. Metab. 310, E452\u2013E460 (2016).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"569_CR160","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/CIRCHEARTFAILURE.109.888479","volume":"3","author":"T Kato","year":"2010","unstructured":"Kato, T. et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 3, 420\u2013430 (2010).","journal-title":"Circ. Heart Fail."},{"key":"569_CR161","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12350-011-9362-3","volume":"18","author":"JB McGill","year":"2011","unstructured":"McGill, J. B. et al. Potentiation of abnormalities in myocardial metabolism with the development of diabetes in women with obesity and insulin resistance. J. Nucl. Cardiol. 18, 421\u2013429; quiz 432\u2013433 (2011).","journal-title":"J. Nucl. Cardiol."},{"key":"569_CR162","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","volume":"130","author":"D Montaigne","year":"2014","unstructured":"Montaigne, D. et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130, 554\u2013564 (2014).","journal-title":"Circulation"},{"key":"569_CR163","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1093\/eurheartj\/ehv442","volume":"37","author":"E Levelt","year":"2016","unstructured":"Levelt, E. et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur. Heart J. 37, 3461\u20133469 (2016).","journal-title":"Eur. Heart J."},{"key":"569_CR164","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia, G., Hill, M. A. & Sowers, J. R. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 122, 624\u2013638 (2018).","journal-title":"Circ. Res."},{"key":"569_CR165","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1194\/jlr.P900032-JLR200","volume":"50","author":"R Marfella","year":"2009","unstructured":"Marfella, R. et al. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J. Lipid Res. 50, 2314\u20132323 (2009).","journal-title":"J. Lipid Res."},{"key":"569_CR166","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/CIRCULATIONAHA.119.043319","volume":"142","author":"D Shao","year":"2020","unstructured":"Shao, D. et al. Increasing fatty acid oxidation prevents high-fat diet-induced cardiomyopathy through regulating parkin-mediated mitophagy. Circulation 142, 983\u2013997 (2020).","journal-title":"Circulation"},{"key":"569_CR167","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.cardiores.2004.11.011","volume":"65","author":"A Planavila","year":"2005","unstructured":"Planavila, A. et al. Peroxisome proliferator-activated receptor beta\/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res. 65, 832\u2013841 (2005).","journal-title":"Cardiovasc. Res."},{"key":"569_CR168","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.2337\/diabetes.54.9.2514","volume":"54","author":"S-Y Park","year":"2005","unstructured":"Park, S.-Y. et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes 54, 2514\u20132524 (2005).","journal-title":"Diabetes"},{"key":"569_CR169","doi-asserted-by":"crossref","first-page":"H305","DOI":"10.1152\/ajpheart.00553.2016","volume":"312","author":"S Kaimoto","year":"2017","unstructured":"Kaimoto, S. et al. Activation of PPAR-\u03b1 in the early stage of heart failure maintained myocardial function and energetics in pressure-overload heart failure. Am. J. Physiol. Heart Circ. Physiol. 312, H305\u2013H313 (2017).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"569_CR170","doi-asserted-by":"crossref","first-page":"44390","DOI":"10.1074\/jbc.M103826200","volume":"276","author":"ME Young","year":"2001","unstructured":"Young, M. E., Laws, F. A., Goodwin, G. W. & Taegtmeyer, H. Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart. J. Biol. Chem. 276, 44390\u201344395 (2001).","journal-title":"J. Biol. Chem."},{"key":"569_CR171","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.106.116871","volume":"321","author":"V Labinskyy","year":"2007","unstructured":"Labinskyy, V. et al. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J. Pharmacol. Exp. Ther. 321, 165\u2013171 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"569_CR172","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","volume":"42","author":"A Deprince","year":"2020","unstructured":"Deprince, A., Haas, J. T. & Staels, B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol. Metab. 42, 101092 (2020).","journal-title":"Mol. Metab."},{"key":"569_CR173","doi-asserted-by":"crossref","first-page":"166097","DOI":"10.1016\/j.bbadis.2021.166097","volume":"1867","author":"A Berthier","year":"2021","unstructured":"Berthier, A., Johanns, M., Zummo, F. P., Lefebvre, P. & Staels, B. PPARs in liver physiology. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166097 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"569_CR174","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.bbalip.2016.03.012","volume":"1861","author":"AN Carley","year":"2016","unstructured":"Carley, A. N. & Lewandowski, E. D. Triacylglycerol turnover in the failing heart. Biochim. Biophys. Acta 1861, 1492\u20131499 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"569_CR175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/CIRCRESAHA.110.221713","volume":"107","author":"NH Banke","year":"2010","unstructured":"Banke, N. H. et al. Preferential oxidation of triacylglyceride-derived fatty acids in heart is augmented by the nuclear receptor PPARalpha. Circ. Res. 107, 233\u2013241 (2010).","journal-title":"Circ. Res."},{"key":"569_CR176","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1161\/CIRCULATIONAHA.114.011687","volume":"130","author":"R Lahey","year":"2014","unstructured":"Lahey, R., Wang, X., Carley, A. N. & Lewandowski, E. D. Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 130, 1790\u20131799 (2014).","journal-title":"Circulation"},{"key":"569_CR177","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","volume":"133","author":"G Aubert","year":"2016","unstructured":"Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698\u2013705 (2016).","journal-title":"Circulation"},{"key":"569_CR178","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124079","volume":"4","author":"JL Horton","year":"2019","unstructured":"Horton, J. L. et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight 4, e124079 (2019).","journal-title":"JCI Insight"},{"key":"569_CR179","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761\u2013772 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"569_CR180","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190\u20131195 (2016).","journal-title":"Diabetes"},{"key":"569_CR181","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego, C. G. et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J. Am. Coll. Cardiol. 73, 1931\u20131944 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"569_CR182","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3892\/ijmm.2015.2270","volume":"36","author":"X Li","year":"2015","unstructured":"Li, X. et al. Treatment with PPAR\u03b4 agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model. Int. J. Mol. Med. 36, 767\u2013775 (2015).","journal-title":"Int. J. Mol. Med."},{"key":"569_CR183","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio, R. E., Chen, E. R. & Lazar, M. A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 20, 573\u2013591 (2014).","journal-title":"Cell Metab."},{"key":"569_CR184","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S. & Stanley, W. C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90, 207\u2013258 (2010).","journal-title":"Physiol. Rev."},{"key":"569_CR185","doi-asserted-by":"crossref","first-page":"29530","DOI":"10.1074\/jbc.273.45.29530","volume":"273","author":"GW Goodwin","year":"1998","unstructured":"Goodwin, G. W., Taylor, C. S. & Taegtmeyer, H. Regulation of energy metabolism of the heart during acute increase in heart work. J. Biol. Chem. 273, 29530\u201329539 (1998).","journal-title":"J. Biol. Chem."},{"key":"569_CR186","first-page":"E309","volume":"257","author":"P Camici","year":"1989","unstructured":"Camici, P. et al. Coronary hemodynamics and myocardial metabolism during and after pacing stress in normal humans. Am. J. Physiol. 257, E309\u2013E317 (1989).","journal-title":"Am. J. Physiol."},{"key":"569_CR187","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.102.8.926","volume":"102","author":"B Bartelds","year":"2000","unstructured":"Bartelds, B. et al. Perinatal changes in myocardial metabolism in lambs. Circulation 102, 926\u2013931 (2000).","journal-title":"Circulation"}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-021-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-021-00569-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-021-00569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T22:03:18Z","timestamp":1672437798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-021-00569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":187,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1038\/s41569-021-00569-6","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"10 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.S. is a consultant for Genfit. D.M. and L.B. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}